Abstract: Recent years have witnessed an improved understanding of tumour biology and the molecular features of gastric cancer. Remarkable advances in next-generation sequencing technologies have defined the genomic landscape of gastric cancer. In fact, several molecular classifications have been proposed, and distinct molecular subtypes have been identified, which could serve as a roadmap for patient stratification and trials of targeted therapies. At present, clinical trials of new agents, such as receptor tyrosine kinases inhibitors, antibodydrug conjugates and IMAB362 (anti-Claudin 18.2), are ongoing. Furthermore, biomarkers of immune checkpoint inhibitors or combination therapy have been ardently investigated. These developments could facilitate precision medicine for gastric cancer in the near future.
Introduction
Gastric cancer (GC) is the fifth most common cancer and the third leading cause of cancerrelated mortality worldwide. 1 Although some chemotherapy (CTx) regimens, including a platinum + fluoropyrimidine combination, trastuzumab [for human epidermal growth factor receptor 2 (HER2)-positive cases], taxanes, irinotecan and ramucirumab, reportedly enhance the survival outcomes of patients with advanced GC (AGC), [2] [3] [4] [5] [6] the prognosis remains poor (median survival ~1 year). Although the phase III ATTRACTION-2 trial of anti-programmed death 1 (anti-PD-1) antibody, nivolumab, reported a survival benefit in AGC, 7 the overall response rate (ORR) was approximately 10% and half of the patients exhibited early disease progression. Thus, the establishment of a better selection of patients who might derive greater benefit from PD-1 blockade is warranted. In addition, trifluridine/tipiracil (TAS-102) demonstrated a survival benefit compared with placebo in heavily pretreated patients with AGC. 8 However, until recently, several phase III trials of targeting agents for AGC failed to demonstrate a survival benefit (Table 1) . Notably, single-agent activity for AGC is minimal, and a few trials have attempted to identify possible biomarkers before phase III trials; thus, better patient stratification based on molecular profiles is crucial.
This study aims to review the molecular features, promising treatment targets and biomarkers of immune checkpoint inhibitors that could facilitate precision medicine for GC in the near future.
Molecular profiles of GC
The molecular characterization of GC has been rapidly evolving recently. To date, several molecular classifications have been proposed, and distinct molecular subtypes have been identified. [9] [10] [11] [12] [13] [14] Reportedly, several receptor tyrosine kinases (RTKs), such as HER2, epidermal growth factor receptor 1 (EGFR), mesenchymal-epithelial transition factor (MET) and fibroblast growth factor receptor 2 (FGFR2), are amplified in GC, and targeted therapies including these molecules have been developed. [15] [16] [17] [18] Notably, these amplifications are frequently but not universally mutually exclusive. [15] [16] [17] [18] In 2014, The Cancer Genome Atlas (TCGA) network characterized 295 gastric adenocarcinoma cases based on six molecular platforms 9 : somatic copy number analysis, whole-exome sequencing, DNA methylation profiling, messenger RNA sequencing, microRNA sequencing and FISH, fluorescence in situ hybridization; EGFR, epidermal growth factor receptor 1; HER2, human epidermal growth factor receptor 2; HGF, hepatocyte growth factor; HR, hazard ratio; IHC, immunohistochemistry; MET, mesenchymal-epithelial transition factor; mTOR, mammalian target of rapamycin; OS, overall survival; PARP, poly (ADP-ribose) polymerase; PBO, placebo; PFS, progression-free survival; STAT3, signal transducer and activator of transcription 3; VEGF, vascular endothelial growth factor; VEGFR2, vascular endothelial growth factor receptor 2. Table 2 ). 10 In the MSS/EMT subtype, nearly 70% of recurrences were at the peritoneum, with a markedly poorer prognosis compared with other subtypes, highlighting the need for therapy development for peritoneal dissemination. 10 34 Furthermore, ctDNA NGS could overcome tissue biopsy errors associated with intratumoural heterogeneity, especially at post-treatment progression.
Lately, antibody-drug conjugates have emerged as a promising strategy in cancer therapy and combine the capability of monoclonal antibodies to precisely target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. Nevertheless, trastuzumab-emtansine (T-DM1, an antibodydrug conjugate comprising trastuzumab linked to the cytotoxic agent DM1), which illustrates remarkable efficacy in breast cancer, did not prolong the OS in HER2-positive AGC; 35 this could be, in part, attributed to intratumoural heterogeneity in the HER2 expression and amplification compared with breast cancer. 23,36 Available evidence indicates that most of HER2-positive GCs are heterogeneous with downregulation in HER2 status post-progression on trastuzumab, as well as diverse intratumoural molecular characteristics. [37] [38] [39] Thus, the assessment of the HER-2 status just before molecular-targeted therapy could be crucial for attaining therapeutic success.
Trastuzumab deruxtecan (DS-8201a) is an antibody-drug conjugate comprising a humanized antibody against HER2, a novel enzyme-cleavable linker and a topoisomerase I inhibitor payload. A preclinical study demonstrated that DS-8201a exerted a potent bystander effect because of a highly membrane-permeable payload and was beneficial in treating tumours with HER2 heterogeneity that are unresponsive to T-DM1. 40 Indeed, a phase I study of DS-8201a exhibited the antitumour activity in patients with breast cancer and AGC previously treated with T-DM1 or trastuzumab, and in patients with HER2-low tumours. 41 In 44 patients with AGC, the overall response rate (ORR), the disease control rate (DCR) and the median PFS were 43.2%, 79.5% and 5.6 months, respectively. 42 A phase II study (DESTINY-Gastric01) in Japan and South Korea assessing the safety and efficacy of DS-8201a in patients with HER2-positive AGC resistant or refractory to trastuzumab is ongoing (ClinicalTrials.gov identifier: NCT03329690).
Recently proposed novel anti-HER2 therapy, ZW25, is reportedly effective and well tolerated in patients with various HER2-positive tumours. 43 ZW25 is a bispecific antibody that concurrently binds two HER2 epitopes: ECD4, the trastuzumab-binding domain, and ECD2, the pertuzumab-binding domain. Preclinical research indicated that ZW25 exhibits potent antitumour activity at a range of HER2 expression levels and could more effectively silence HER2 signalling than trastuzumab or pertuzumab and stimulates the immune system. A phase I trial reported a response rate of 38% in heavily pretreated HER2-expressing tumours including GC. 44 Further assessment in HER2-positive tumours, including AGC, is ongoing.
In a preclinical study, combining anti-PD-1 and anti-HER2 therapy induce T-cell activation and augment ADCC. 45 A phase II trial of the addition of trastuzumab + pembrolizumab to the first-line CTx exhibited promising results with ORR of 87% and the median PFS of 11.4 months, which warrants further evaluation in an ongoing phase III trial (KEYNOTE811; ClinicalTrials.gov identifier: NCT03615326).
Other RTKs
Up to 60% of GC cases belong to the CIN subtype, which is commonly related to abnormalities on RTKs signalling. [9] [10] [11] [12] [13] [14] [15] The lack of appropriate patient selection and molecular stratification could be one of the reasons for the failure in these trials. Considering that the amplification of RTKs does not simply correlate with the protein expression in GC, 17 a comprehensive analysis using both NGC and IHC could be necessary to select patients adequately.
VEGF targeting therapy
Ramucirumab is a human IgG1 monoclonal antibody specific for vascular endothelial growth factor receptor 2 (VEGFR2), which has recently been validated to be effective for AGC by the REGARD and RAINBOW trials. 4, 6 In the RAINBOW trial, which compared paclitaxel + placebo with paclitaxel + ramucirumab, patients treated with paclitaxel + ramucirumab exhibited significantly longer OS (median, 9.6 versus 7.4 months), longer PFS (median, 4.4 versus 2.9 months) and higher response rate (28% versus 16%) than those treated with paclitaxel alone. Regrettably, an optimal biomarker for antiangiogenic treatment is still lacking.
A recent retrospective exploratory analysis from the REGARD study reported that none of the tested biomarkers (tumour HER2 or VEGFR2 and serum VEGF-C and VEGF-D, and soluble VEGFR1 and VEGFR3) identified a potent predictive biomarker of ramucirumab efficacy. 59 Moreover, per the exploratory plasma analyses from the RAINBOW study, neither VEGF pathway markers nor other markers revealed a predictive correlation with ramucirumab efficacy. 60 Recently, the RAINFALL phase III trial demonstrated that adding ramucirumab to first-line cisplatin/fluoropyrimidine did not exhibit enhanced OS, which also failed to exhibit the utility of plasma biomarkers, such as VEGF-C and VEGF-D. 61 A phase III double-blind placebo-controlled study of regorafenib, multiple VEGF TKIs in patients with AGC is underway, which will also assess predictive biomarkers of this antiangiogenic treatment. Furthermore, apatinib is a multikinase inhibitor that primarily targets VEGFR2 and markedly enhances OS in patients with pretreated AGC, although no biomarkers were identified to predict clinical benefits. 62
PARP inhibitor
The GC pathogenesis is associated with DNA damage and chronic inflammation from Helicobacter pylori 63, 64 and EBV infections, 65 to lifestyle factors including obesity and chronic gastric acid reflux. Large-scale genome sequencing of GC suggested that somatic mutations in genes involved in homologous recombination DNA repair are common features. 9, 10 Olaparib is an oral poly (ADP-ribose) polymerase (PARP) inhibitor that blocks DNA base-excision repair and causes synthetic lethality in tumours with homologous recombination repair deficiencies. Ataxia-telangiectasia mutated (ATM) is a gene essential to the cellular double-strand DNA breaks response essential to maintain genome stability levels. In a phase II trial of olaparib combined with paclitaxel versus placebo combined with paclitaxel as second-line therapy, a higher OS benefit was noted in AGC patients with ATM-negative tumours (HR 0.35; p = 0.002). 66 Unfortunately, the phase III GOLD trial did not report improved OS with olaparib in patients with ATM-negative tumours (HR 0.73; p = 0.25) as well as overall population (HR 0.79, p = 0.026), 67 indicating that patient selection by the ATM status was not sufficient. Biomarker analysis of the GOLD study revealed that none of the other genetic markers of DNA damage repair, which have proven predictive in other tumour types for full-dose olaparib monotherapy, correlated with the sensitivity to low-dose olaparib combination with paclitaxel in patients with AGC. 68 A phase III trial comparing PARP inhibitor BGB-920 with placebo as maintenance therapy in patients with AGC who responded to first-line platinumbased CTx is under way, which would also assess the sensitivity to PARP inhibitor monotherapy from tumour specimen. Based on a preclinical study demonstrating that PARP inhibitor upregulates the PD-L1 expression on tumour cells, 69 a phase II trial of olaparib and anti-PD-L1 antibody, durvalumab, was conducted, resulting in an ORR of 10% and a DCR of 25% after 12 weeks because of a high rate of early disease progression following olaparib monotherapy for 4 weeks, 70 which will be explored in combination with CTx.
Targeting therapy for stemness-related pathway or cancer stroma Cancer stem cells (CSCs) exhibit self-renewal capability and could contribute to malignant tumour growth, disease relapse and metastasis. Signal transducer and activator of transcription 3 (STAT3) activation is one of the hallmarks associated with cancer 'stemness'. STAT3 acts as a transcription factor located downstream of various pro-oncogenic cytokines and JAK. Reportedly, phosphorylated STAT3 activates the transcription of Nanog and Myc genes. 71 BBI608 (napabucasin) is an orally administered investigational small molecule presumed to affect multiple oncogenic cellular pathways, including the inhibition of STAT3, which has been implicated in providing CSCs with stemness characteristics. 71 Encouraging the antitumour activity of BBI608 and paclitaxel in refractory AGC was observed in a phase Ib and subsequent phase II study with an ORR of 31% and a DCR of 75%. 72 Nevertheless, a phase III trial (BRIGHTER) of BBI608 + weekly paclitaxel versus placebo + weekly paclitaxel in patients with AGC failed to improve the OS. 73 Reportedly, a subpopulation of gastric carcinoma cells expressing EPCAM, CD44, CD44 variant (CD44v), CD133 and CD166 exhibited the properties to generate new heterogeneous tumours in vitro. 74 Sulfasalazine is an inhibitor of the cysteineglutamate exchange transporter, a variant form of CD44v. Sulfasalazin induces a reduction in CD44v-positive cells and intracellular reduced glutathione levels in patients with AGC. 75 However, a phase I trial of the combination of sulfasalazin with cisplatin in patients with CD44v-expressing AGC refractory to cisplatin did not exhibit an apparent antitumour activity. 76 Recently, Nanki et al. illustrated divergent genetic and epigenetic routes to gain Wnt and R-spondin niche independency in phenotype analyses of GC organoids, and a marked correlation between CDH1/TP53 compound mutations, which were also identified in the TCGA 2014 report, 9 and R-spondin independency (Wnt-dependent GC). 77 In this study, xenografting of GC organoids established the feasibility of Wnt-targeting therapy for Wnt-dependent GC. 77 Most recently, a preclinical study reported that the Wnt receptor Fzd7 is a promising target for GC irrespective of the APC mutation status. 78 Dickkopf-1 (DKK1) is a modulator of the Wnt and PI3K-AKT signalling pathways and contributes to an immunosuppressive tumour microenvironment by activating MDSCs and regulatory T cells (Tregs). DKN-01, a monoclonal antibody against DKK1, acts on innate immune cells, and a preclinical study illustrated the upregulation of both PD-L1 and IFN-γ-related chemokines, indicating a rational for immune checkpoint combination. A phase Ib trial of DKN-01 in combination with pembrolizumab reported encouraging antitumour activity in AGC with an ORR of 23.5% and a DCR of 58.8%, which warrants further investigation. 79 
MMP-9
Matrix metalloproteinases-9 (MMP-9) is an extracellular enzyme involved in matrix remodelling, angiogenesis, tumour growth and metastasis. 80 Chen et al. reported a higher expression of MMP-9 in the GC tissue than that in the adjacent healthy tissues. 81 Moreover, its overexpression reportedly correlated with the poor prognosis of GC. 82 Preclinical studies demonstrated that MMP-9 inhibition alters the tumour microenvironment, which correlates with higher CTx penetration and enhanced antitumour immunity. Andecaliximab is a monoclonal antibody that inhibits MMP-9 and has been combined with various CTx regimens. A phase I/Ib trial of mFOLFOX6+ andecaliximab revealed encouraging antitumour activity in AGC patients with the median PFS of 9.9 months in the first-line setting and the ORR of 50%. 83 However, a subsequent phase III study of andecaliximab combined with mFOLFOX6 in the first-line setting for patients with AGC did not markedly improve the OS. 84 Claudin 18.2 Claudin18.2 (CLDN18.2) is a member of the claudin family of >20 structurally related proteins that form vital components of the tight cell journals.sagepub.com/home/tam 9 junctions in epithelia and endothelia; 85 it is not expressed in any healthy tissue, except the stomach mucosa, but broadly expressed in various cancer types including AGC, especially in diffusetype GCs. 86 Moreover, CLDN18-ARHGAP26/6 fusions have been identified in GCs, with a predominance in GS-type tumours based on the TCGA classification. 9 Reportedly, almost all CLDN18-ARHGAP26/6 fusion-positive GCs expressed CLDN18.2 protein with a higher prevalence of lymphatic and distant organ metastases, especially in the younger age patients. 87 Furthermore, the TCGA data demonstrated that the CLDN18-ARHGAP26/6 fusion was mutually exclusive with driver genes, such as RHOA and CDH1 mutations, which were frequently noted in GS-type tumours. 9
IMAB362 (zolbetuximab) is a novel chimeric IgG1 antibody highly specific for CLDN18. 
Immune checkpoint inhibitors and its biomarkers
Recently, blockade of immune checkpoint molecules with monoclonal antibodies has emerged as a promising strategy in several malignancies. [92] [93] [94] [95] [96] [97] PD-1, which belongs to the CD28 family of proteins, is a negative costimulatory receptor expressed on the surface of activated T cells. 98 The binding of PD-1 and its ligands, PD-L1 and PD-L2 in tumour or immune cells, can inhibit a cytotoxic T-cell response, which leads tumour cells to escape from immune surveillance. 98 Accordingly, the blockade of this interaction restores the antitumour activity of T cells. 98 Clinical trials of anti-PD-1/PD-L1 monoclonal antibodies have reported durable antitumour response and enhanced OS in several malignancies. [92] [93] [94] [95] [96] [97] A phase III ATTRACTION-2 trial of nivolumab, a fully human IgG4 monoclonal antibody against PD-1, for patients with AGC after two or more previous line CTxs demonstrated a survival benefit, resulting in the approval of nivolumab for AGC in Japan as third-line or later-line treatment. 7 However, subsequent randomized trial of anti-PD1/PD-L1 in earlier trials failed to exhibit a survival benefit compared with standard CTx; thus, better treatment selection is warranted to use anti-PD1/PD1 in earlier treatment lines.
PD-L1 expression
An exploratory analysis of ATTRACTION-2 indicated no predictive value of PD-L1 expression on tumour cells. 7 Moreover, in JAVELIN 300, which recently failed to establish a survival benefit for avelumab compared with the investigators' choice of CTx with paclitaxel or irinotecan for patients with AGC, no difference was observed in the OS based on the PD-L1 expression, which was defined as PD-L1 staining on 1% of tumour cells. 99 Results remained the same when PD-L1 was also assessed on immune cells, although the methodology for this assessment is not described. However, a correlation between higher PD-L1 expression [using the combined positive score (CPS), which is a proportional assessment of PD-L1 staining on both tumour and immune cells] and higher treatment effect was suggested in phase II (KEYNOTE-059) and III trials (KEYNOTE-061) of pembrolizumab. 96, 100 In KEYNOTE-059, the ORR in the third-line setting was 22.7% for patients with PD-L1 expression (CPS ⩾1) as determined by 22C3 IHC assay, whereas the ORR was 8.6% for those with PD-L1-negative tumours, resulting in US Food and Drug Administration (FDA) approval of pembrolizumab for PD-L1-positive AGC and PD-L1 22C3 IHC as a companion diagnostic assay. 96 Although KEYNOTE-061 failed to demonstrate improvement in the OS with pembrolizumab in CPS ⩾1 population, patients who expressed high levels of PD-L1 (CPS ⩾10) exhibited a pronounced benefit from treatment with pembrolizumab (HR 0.64; 95% CI 0.41-1.02). 100 The ORRs of pembrolizumab in patients with CPS ⩾10, CPS ⩾1 and CPS <1 (PD-L1-negative) were 25%, 16% and 2%, respectively. 36 The impact of CPS on the efficacy of PD-1 blockade will also be assessed in the ongoing phase III trial (KEYNOTE-062), which compared the efficacy of cytotoxic agents combined with pembrolizumab with that of cytotoxic agents and pembrolizumab monotherapy in patients with untreated AGC (ClinicalTrials.gov identifier: NCT02494583). This study might offer some insights into how to select patients for single-agent immunotherapy or combination with CTx.
In the AGC cohort of CheckMate-032, 101 the ORR was the highest with 1 mg/kg nivolumab + 3 mg/kg ipilimumab (24%), relative to 3 mg/kg nivolumab (12%) or 3 mg/kg nivolumab + 1 mg/kg ipilimumab (8%) cohorts. The ORR seemed numerically higher in patients with PD-L1-positive on tumour cells (⩾1% PD-L1 staining of tumour cell membranes) than PD-L1-negative responses. Other combinations therapy might be necessary to enhance outcomes in PD-L1 negative patients.
MSI-H
As shown in the TCGA 2014 and ACRG 2015 reports, the MSI-H subtype exhibits frequent mutations in multiple genes (including frameshifts or missense mutations) and hypermethylation (including hypermethylation at the MLH1 promoter), which contribute to the enhanced expression of neoantigens. MSI-H/MMR-D colorectal cancer has higher mutation loads than that of MSS/MMR proficient (MMR-P) colorectal cancer, resulting in high infiltration of CD8+ T cells presumably because of the recognition of a high number of tumour neoantigens and its corresponding expression of immune checkpoints in the tumour microenvironment. 102 Indeed, the FDA approved pembrolizumab for patients with MSI-H or MMR-D solid tumours, including AGC based on the durable response in several trials. [103] [104] [105] Recently, pembrolizumab for patients with MSI-H/MMR-D solid tumours was approved in Japan also. In a phase II KEYNOTE-158 trial of pembrolizumab demonstrating that the ORR was 37.2% for 94 patients with MSI-H/MMR-D noncolorectal solid tumours, including patients in Japan, 6 of 13 patients with AGC attained an objective response (ORR 46.2%). Moreover, a subgroup analysis of KEYNOTE-059 and KEYNOTE-061 revealed that the ORR was 57.1% and 46.7% for patients with MSI-H/ MMR-D AGC, respectively. 96, 100 Based on this evidence, Pan-Asian adapted the ESMO Clinical Practice Guidelines for the management of patients with metastatic GC and recommended that pembrolizumab or nivolumab could be a treatment option for patients with MSI-H/ MMR-D AGC in second-line settings. 106 Other factors to predict response As patients with MSI-H/MMR-D form a small minority of AGC patients, novel biomarkers to predict response to immunotherapy among MSS/ MMR-P are desired. A recent study reported that tumour mutation burden (TMB) correlated with enhanced survival in patients receiving immune checkpoint inhibitors across multiple cancer types. 107 Moreover, Kim et al. reported that TMB was a potential biomarker of pembrolizumab for AGC. 108 However, most patients with high TMB had MSI-H/MMR-D status, and not all patients with high TMB attained an objective response. 108 Hence, the precise mechanism regarding the impact of TMB on the efficacy of PD-1/PD-L1 blockade should be investigated in the near future. The TCGA reported that the amplification of the CD274 gene (which encodes PD-L1) and the PDCD1LG2 gene (which encodes PD-L2) was frequently observed in EBV-positive GC. 9 Indeed, AGC patients with EBV-positive status reported derived higher benefit from pembrolizumab. 108 Notably, Panda et al. reported that a patient with EBV-positive AGC exhibited durable response from treatment with the anti-PD-L1 antibody avelumab, although this tumour had low mutation journals.sagepub.com/home/tam 11 burden. 109 A study recently reported that the ORR of nivolumab for AGC after two or more CTx regimens was significantly higher in patients with MMR-D than in those with MMR-P (75% versus 13%), PD-L1+ in tumour cells than in those with PD-L1-in tumour cells (57% versus 13%) and PIK3CA mutation in those with PIK3CA wildtype (44% versus 14%). 110 Remarkably, the ORR was 31% in patients with, at least, one of the following factors: MMR-D, high-TMB, EBVpositive and PD-L1+ in tumour cells versus 0% in those without these factors, suggesting that prescreening of these biomarkers could be useful in predicting the clinical benefit of the anti-PD-1/ PD-L1 blockade in AGC. Moreover, the diversity and composition of gut microbiome reportedly predicts the effect of PD-1 blockade in patients with AGC. 111 A recent subgroup analysis of ATTRACTION-2 indicated that patients with hyponatraemia along with high neutrophil-tolymphocyte ratio might exhibit low benefit with nivolumab in terms of early progression and death. 112 
Controversy in hyperprogressive disease
Recently, anti-PD-1/PD-L1 antibodies have anecdotally been reported to cause rapid progression of some cancer types, which is called hyperprogressive disease (HPD), [113] [114] [115] [116] although its exact incidence in GC remains unclear. As HPD, perhaps, correlates with poor prognoses, it is imperative to identify predictive factors of HPD. Kato et al. identified EGFR mutations and MDM2 amplification as possible molecular predictors of HPD in patients with several solid tumours. 115 Reportedly, FBXW7 mutation or KRAS amplification could be related to HPD in patients with AGC who received nivolumab. 117 Recently, Togashi et al. reported an increase in Tregs with proliferative capacity among tumour-infiltrating lymphocytes in AGC patients who exhibited HPD after treatment with an anti-PD-1 antibody. 118 Moreover, an in vitro study reported that PD-1 blockade activated not only effector T cells but also Tregs, which promoted tumour progression in a fraction of patients. 118 
